In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
After the phase I/II, the sponsor is designing the phase III clinical trial of an antisense oligonucleotide in cancer patients.
Is it possible to develop a solid population pharmacokinetic model using phase I/II data to design a sparse sampling scheme for phase III clinical trials?
Nonlinear mixed-effects modeling was used to build the pharmacokinetic model with phase I/II data. An optimization algorithm was used to find the optimal sampling scheme.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved